Literature DB >> 23536980

Risk factors for respiratory syncytial virus illness among patients with chronic obstructive pulmonary disease.

Jyotsna Mehta1, Edward E Walsh, Parthiv J Mahadevia, Ann R Falsey.   

Abstract

Respiratory syncytial virus (RSV), although not typically considered an important pathogen in adults, may cause acute exacerbation of chronic obstructive pulmonary disease (COPD). It is unclear which COPD patients are at highest risk for developing serious RSV illness. Our objective was to identify risk factors for RSV illness among adult patients with COPD. We conducted a pooled analysis of data from COPD patients in 2 previously published longitudinal studies that examined RSV infection in high risk adults for ≤ 2 RSV seasons. Risk factors for RSV illness studied included age, sex, race, smoking status, exposure to children, home oxygen use, inhaled or oral steroid use, instrumental activities of daily living scores, and co-morbid conditions. Outcomes studied included symptomatic and medically attended RSV illness. Logistic regression was used to identify significant risk factors for RSV illness among older adults with COPD. Among 379 patients with COPD, the rate of symptomatic RSV illness was 11.1% (42/379); almost half (20/42) of whom required medical attention. In multivariable analyses, congestive heart failure (odds ratio [OR] = 4.18; 95% CI: 1.38, 12.69) and exposure to children (OR = 2.38; 95% CI: 1.03, 5.51) were risk factors for symptomatic RSV illness. Congestive heart failure (OR = 4.16; 95% CI: 1.02, 17.01) was the only significant risk factor for developing medically attended RSV illness. Exposure to children and congestive heart failure are risk factors for RSV illness among adult patients with COPD. Future prospective, well-designed studies are needed to corroborate these findings and examine other risk factors, including history of exacerbations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23536980     DOI: 10.3109/15412555.2012.744741

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  21 in total

1.  Respiratory syncytial virus infection in older adults: an under-recognized problem.

Authors:  Angela R Branche; Ann R Falsey
Journal:  Drugs Aging       Date:  2015-04       Impact factor: 3.923

2.  T-Cell Responses in Adults During Natural Respiratory Syncytial Virus Infection.

Authors:  D Roumanes; A R Falsey; S Quataert; S Secor-Socha; F E-H Lee; H Yang; S Bandyopadhyay; J Holden-Wiltse; D J Topham; E E Walsh
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

3.  Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor.

Authors:  Matthew Coates; Daniel Brookes; Young-In Kim; Heather Allen; Euan A F Fordyce; Elizabeth A Meals; Thomas Colley; Claire-Lise Ciana; Guillaume F Parra; Vladimir Sherbukhin; Jennifer A Stockwell; Jennifer C Thomas; S Fraser Hunt; Lauren Anderson-Dring; Stuart T Onions; Lindsey Cass; Peter J Murray; Kazuhiro Ito; Pete Strong; John P DeVincenzo; Garth Rapeport
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

4.  Impact of respiratory viral infections on mortality and critical illness among hospitalized patients with chronic obstructive pulmonary disease.

Authors:  Sunita Mulpuru; Melissa K Andrew; Lingyun Ye; Todd Hatchette; Jason LeBlanc; May El-Sherif; Donna MacKinnon-Cameron; Shawn D Aaron; Gonzalo G Alvarez; Alan J Forster; Ardith Ambrose; Shelly A McNeil
Journal:  Influenza Other Respir Viruses       Date:  2022-09-07       Impact factor: 5.606

5.  Seroprevalence of respiratory syncytial virus IgG among healthy young adults in basic training for the Republic of Korea Air Force.

Authors:  Won-Ju Park
Journal:  J Korean Med Sci       Date:  2014-09-02       Impact factor: 2.153

6.  Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study.

Authors:  John DeVincenzo; Lindsey Cass; Alison Murray; Kathy Woodward; Elizabeth Meals; Matthew Coates; Leah Daly; Vicky Wheeler; Julie Mori; Charlie Brindley; Amanda Davis; Meabh McCurdy; Kazuhiro Ito; Bryan Murray; Pete Strong; Garth Rapeport
Journal:  J Infect Dis       Date:  2022-06-15       Impact factor: 7.759

Review 7.  The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: A systematic review.

Authors:  Ann D Colosia; Jin Yang; Eric Hillson; Josephine Mauskopf; Catherine Copley-Merriman; Vivek Shinde; Jeffrey Stoddard
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

8.  Clinical characteristics and outcome of respiratory syncytial virus infection among adults hospitalized with influenza-like illness in France.

Authors:  P Loubet; N Lenzi; M Valette; V Foulongne; A Krivine; N Houhou; G Lagathu; S Rogez; S Alain; X Duval; F Galtier; D Postil; P Tattevin; P Vanhems; F Carrat; B Lina; O Launay
Journal:  Clin Microbiol Infect       Date:  2016-11-27       Impact factor: 8.067

9.  Respiratory syncytial virus infections enhance cigarette smoke induced COPD in mice.

Authors:  Robert F Foronjy; Abdoulaye J Dabo; Clifford C Taggart; Sinead Weldon; Patrick Geraghty
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

10.  Respiratory syncytial virus infection-associated hospitalization in adults: a retrospective cohort study.

Authors:  Cheryl Volling; Kazi Hassan; Tony Mazzulli; Karen Green; Ahmed Al-Den; Paul Hunter; Rupi Mangat; John Ng; Allison McGeer
Journal:  BMC Infect Dis       Date:  2014-12-13       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.